# Italy RNA-based Therapeutics Market

> Italy RNA-Based Therapeutics Market Research Report: Size, Share, Trend Analysis By Technology (RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, CRISPR Technology), By Applications (Oncology, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases), By End Use (Pharmaceutical Companies, Research Institutions, Contract Research Organizations) and By Delivery Method (Liposomes, Nanoparticles, Viral Vectors, Electroporation) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.44%
- **2024:** $ 439.59 Million
- **2025:** $ 467.9 Million
- **2035:** $ 873.25 Million
- **Key Players:** Moderna (US), BioNTech (DE), Alnylam Pharmaceuticals (US), Ionis Pharmaceuticals (US), Sangamo Therapeutics (US), CureVac (DE), Arcturus Therapeutics (US), Translate Bio (US)

**Report ID:** MRFR/HC/50894-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/italy-rna-based-therapeutics-market-52653

---

## Market Summary

## **Italy RNA-Based Therapeutics Market Overview**

As per MRFR analysis, the Italy RNA-Based Therapeutics Market Size was estimated at 192.5 (USD Million) in 2023. The Italy RNA-Based Therapeutics Market Industry is expected to grow from 212.25 (USD Million) in 2024 to 525 (USD Million) by 2035. The Italy RNA-Based Therapeutics Market CAGR (growth rate) is expected to be around 8.581% during the forecast period (2025 - 2035).

### **Key Italy RNA-Based Therapeutics Market Trends Highlighted**

The RNA-Based Therapeutics Market in Italy is experiencing significant growth driven by advancements in molecular biology and increased funding for research and development. The Italian government has been supportive of bio-pharmaceutical innovations, with national funding mechanisms aimed at fostering collaborations between academic institutions and industry leaders. This backing enhances the research capabilities within the country and fosters a robust ecosystem for developing RNA-based treatments.

Additionally, Italy's well-established pharmaceutical sector plays a crucial role in the market, encouraging local companies to invest more in RNA technology. Recent trends indicate a growing focus on personalized medicine, with RNA therapeutics being tailored to individual genetic profiles to address specific diseases. There is also a notable increase in clinical trials for RNA-based drugs, reflecting a shift toward targeted treatments for conditions such as cancer, genetic disorders, and infectious diseases, important areas of concern in Italy’s healthcare landscape.

Furthermore, the surge in collaborations between biotechnology firms and academic institutions is fostering an innovation-rich environment that is conducive to breakthroughs in RNA therapeutics. Opportunities are present in expanding public and private partnerships, which could accelerate the commercialization of RNA-based therapies. Italian companies are encouraged to leverage the country's robust bio-pharmaceutical infrastructure and skilled workforce to tap into the global market.

The increasing focus on rare diseases within the Italian healthcare system also presents a ripe opportunity for developing RNA therapies that are designed for niche markets. The evolving regulatory framework and increased understanding of RNA biology are paving the way for more efficient development processes, promising a dynamic future for the RNA-based therapeutics market in Italy.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Italy RNA-Based Therapeutics Market Drivers**

#### **Increasing Investment in Research and Development**

The Italy RNA-Based Therapeutics Market Industry is experiencing significant growth driven by increased investment in Research and Development (R&D). The Italian government has recognized the potential of RNA-based therapies and has allocated substantial funding to biotech initiatives, with a reported increase of 15% in public funding for life sciences in 2022. Organizations like Italian Institute of Technology (IIT) are leading emerging projects in RNA therapeutics, aiming to translate academic research into clinical applications.

This heightened focus on R&D is expected to bolster innovation and bring new RNA-based therapies to market, enhancing the overall growth of the industry in Italy.

#### **Rising Prevalence of Genetic Disorders**

The increasing prevalence of genetic disorders is a significant driver for the Italy RNA-Based Therapeutics Market Industry. According to data from the Italian Ministry of Health, genetic diseases affect approximately 1 in 2,000 births in Italy, representing a rising concern for public health. Italy's National Health System has begun to prioritize genetic research and the development of RNA therapeutics as viable treatment solutions.

This focus has catalyzed advancements and clinical trials in RNA-based treatments, fostering a favorable environment for market expansion.

#### **Expansion of Personalized Medicine**

The push towards personalized medicine is having a profound impact on the Italy RNA-Based Therapeutics Market Industry. With healthcare systems increasingly recognizing the value of tailored treatments, RNA-based therapies are at the forefront of this trend. The Italian Medicines Agency (Agenzia Italiana del Farmaco) has been promoting initiatives for individualized treatment protocols, aiming to meet the diverse needs of patients.

This transition is expected to drive demand for RNA therapeutics, as they offer the potential to be customized to the genetic makeup of individual patients, ultimately leading to improved therapeutic outcomes.

#### **Growth of Biotech Startups and Collaborations**

Biotech companies in Italy are helping to drive the RNA-Based Therapeutics Market. Driven by government incentives and support from organizations including the Italian Trade Agency, recent studies reveal that the number of biotech companies in Italy has doubled over the last ten years. These businesses are more and more concentrating on RNA technology and working with seasoned pharmaceutical corporations to provide creative treatments.

Such partnerships not only enhance resource allocation but also accelerate the development of RNA-based solutions in Italy, contributing to a vibrant market landscape.

### **Italy RNA-Based Therapeutics Market Segment Insights**

#### **RNA-Based Therapeutics Market Technology Insights**

The Technology segment within the Italy RNA-Based Therapeutics Market has seen robust growth, driven by advancements in genetic research and the increasing prevalence of genetic disorders. RNA interference (RNAi) stands out prominently in this landscape, as it offers a targeted approach to gene silencing, holding transformative potential for treating various diseases, including cancers and viral infections. Antisense oligonucleotides (ASOs) also play a critical role, as they are designed to bind to specific RNA molecules, effectively modulating gene expression.

This methodology not only highlights the significance of precision medicine but also demonstrates Italy’s commitment to advancing health outcomes through innovative therapeutic approaches. Moreover, the emergence of mRNA therapeutics, boosted by attention due to successful vaccine developments, leads to broader implications for treating infectious diseases and cancer therapies. The potential for mRNA platforms to enable rapid responses to health crises shows significant promise for the Italian bio-pharmaceutical sector.

Lastly, CRISPR Technology remains a game changer in genetic editing, showcasing Italy's dedication to pioneering methods that could lead to groundbreaking treatments for genetic disorders. The intersection of these technologies fosters a rich environment for Research and Development (R&D) initiatives, supported by various public and private sectors in Italy, which aim to bring forth effective and scalable therapeutic solutions.

As the RNA-Based Therapeutics Market continues to evolve in Italy, these technology segments will be pivotal in addressing unmet medical needs, enhancing treatment efficacy, and ultimately contributing to improved patient outcomes on a national and global scale.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

#### **RNA-Based Therapeutics Market Application Insights**

The Application segment of the Italy RNA-Based Therapeutics Market plays a pivotal role in addressing critical health challenges faced by the population. This segment encompasses diverse areas such as Oncology, Infectious Diseases, Genetic Disorders, and Cardiovascular Diseases, each contributing significantly to the overall market landscape. Oncology remains a crucial focus due to the rising prevalence of cancer, driving research and innovation in RNA-based therapies designed to target specific cancer cells while minimizing damage to healthy tissue.

Infectious Diseases represent another vital area, particularly in light of recent global health crises, highlighting the need for rapid-response therapeutics that can combat emerging pathogens effectively. The focus on Genetic Disorders is underscored by advancements in gene therapy techniques, giving hope to patients with previously untreatable hereditary conditions. Similarly, Cardiovascular Diseases are prioritized, as RNA-based solutions promise to address common issues such as heart disease and related complications, offering more tailored treatment options.

These applications indicate a robust future for the Italy RNA-Based Therapeutics Market, fueled by the demand for personalized medicine and ongoing advancements in biotechnology.

#### **RNA-Based Therapeutics Market End Use Insights**

The End Use segment of the Italy RNA-Based Therapeutics Market plays a vital role in shaping the landscape of healthcare innovations within the region. Pharmaceutical companies are pivotal in the development and commercialization of novel RNA-based therapies, leveraging their extensive capabilities in research and development, clinical trials, and distribution networks. Their investments not only drive technological advancements but also enhance patient access to innovative treatments.

Research institutions contribute significantly by advancing the fundamental understanding of RNA mechanisms, helping to identify new therapeutic targets and validate emerging RNA technologies. Furthermore, Contract Research Organizations, or CROs, provide essential support services to both pharmaceutical companies and research institutions, facilitating timely and cost-effective clinical trials. This interdependence among various participants in the market fosters a collaborative ecosystem that accelerates innovation in RNA therapeutics, a field crucial for addressing genetic disorders and improving healthcare outcomes in Italy.

The market is expected to witness significant advancements driven by ongoing research and potential groundbreaking therapies that could reshape treatment paradigms.

#### **RNA-Based Therapeutics Market Delivery Method Insights**

The Delivery Method segment of the Italy RNA-Based Therapeutics Market is pivotal in ensuring effective therapeutic outcomes and improving patient experiences. Among the various methods, Liposomes are noteworthy due to their ability to encapsulate RNA molecules and enhance cellular uptake, significantly aiding targeted delivery. Nanoparticles are emerging as a dominant choice, owing to their versatile properties that enable controlled release and the ability to cross biological barriers, which is crucial for reaching specific tissues in the body effectively.

Viral Vectors are also gaining traction as they provide a natural mechanism for delivering RNA into cells, making them efficient for gene therapy applications. Electroporation stands out for its ability to create temporary pores in cell membranes, facilitating the direct introduction of RNA therapeutics. Overall, the innovations in these delivery methods are enhancing the effectiveness of RNA-based therapies in Italy, as the market continues to grow and adapt to the needs for safer and more efficient treatment options.

The Italy RNA-Based Therapeutics Market segmentation reflects a commitment to addressing the unique challenges in drug delivery, creating ample opportunities for advancements in patient care and therapeutic efficacy.

### **Italy RNA-Based Therapeutics Market Key Players and Competitive Insights**

The Italy RNA-Based Therapeutics Market has been witnessing significant growth, influenced by advancements in biotechnology and increased investment in research and development. The market is characterized by a dynamic competitive landscape, with several key players striving to innovate and expand their product offerings. The rise in chronic diseases and the demand for personalized medicine have propelled various companies to focus on RNA-based therapeutics, offering novel solutions for treating genetic disorders, cancer, and infectious diseases.

Competitive insights reveal that the market is driven by the need for effective, targeted treatments that harness the potential of RNA molecules, leading to a surge in collaborations, mergers, and strategic partnerships among industry participants. Companies are also focusing on improving delivery systems and enhancing the stability of RNA therapeutics to address challenges associated with their clinical application.

Sarepta Therapeutics is prominently positioned within the Italy RNA-Based Therapeutics Market, known for its innovative approaches in developing therapies that address rare genetic disorders. The company's strength lies in its commitment to advancing RNA-targeted therapeutics, particularly gene therapies that utilize synthetic RNA constructs to promote muscle health and function. Sarepta's robust pipeline includes several investigational products aimed at treating conditions such as Duchenne Muscular Dystrophy, reflecting the company’s strong foothold in the market.

In Italy, Sarepta has established significant collaborations with local research institutions and healthcare providers, enhancing its visibility and fostering a knowledge exchange that boosts its research capabilities. This strategic engagement not only solidifies Sarepta’s presence in the region but also contributes to the broader ecosystem of RNA-based therapeutic development.

OncoOne is another key player in the Italy RNA-Based Therapeutics Market, specializing in innovative cancer therapeutics. The company is recognized for its focus on cancer detection and treatment solutions, particularly utilizing RNA in the development of diagnostic biomarkers and therapeutic agents. OncoOne's key products include personalized RNA-based therapies that target specific cancer pathways, leading to tailored treatment options based on individual patient profiles.

The company has built a strong market presence through strategic partnerships and collaborations with Italian healthcare institutions, allowing it to leverage local expertise and resources in its research and development processes. Recent mergers and acquisitions have further strengthened OncoOne's position, enhancing its operational capabilities and expanding its portfolio of services. This strategic approach positions OncoOne as a significant contributor to the advancement of RNA-based therapeutics in Italy, underscoring its commitment to innovation in the oncology sector.

### **Key Companies in the Italy RNA-Based Therapeutics Market Include**

### **Italy RNA-Based Therapeutics Market Industry Developments**

The Italy RNA-Based Therapeutics Market has witnessed significant developments in recent months, showcasing advancements and collaborations among key players. For instance, in October 2023, BioNTech announced a partnership with Italian research institutions to enhance RNA therapy for cancer treatment, signaling a commitment to local innovation. Meanwhile, Moderna continues to expand its footprint in Italy, particularly in the realm of messenger RNA-based vaccines and treatments.

The growth of companies such as Alnylam Pharmaceuticals and Silence Therapeutics in the region has contributed to the market's valuation, with increasing investments and research initiatives. Notably, there have been no major merger or acquisition activities reported in Italy among the focused companies recently. However, Dicerna Pharmaceuticals recently received regulatory approval for its RNA-based therapy targeting rare genetic disorders, further highlighting the dynamic landscape of the market.

The Italian government's support for biotechnology through funding initiatives and regulatory reforms has fostered a favorable environment for these companies to thrive. The combination of local research efforts and multinational partnerships is pivotal for driving growth and innovation within the RNA-Based Therapeutics sector in Italy.

### **Italy RNA-Based Therapeutics Market Segmentation Insights**

#### **RNA-Based Therapeutics Market Technology Outlook**

#### **RNA-Based Therapeutics Market Application Outlook**

#### **RNA-Based Therapeutics Market End Use Outlook**

#### **RNA-Based Therapeutics Market Delivery Method Outlook**

## Market Drivers

### Supportive Government Policies

The Italian government is actively promoting the development of innovative therapies, including rna-based treatments, through supportive policies and funding initiatives. This includes grants and incentives for research institutions and biotech companies engaged in rna research. Such governmental support is crucial for fostering innovation and accelerating the commercialization of rna-based therapies. The RNA-based therapeutics market is likely to benefit from these initiatives, with an anticipated increase in funding allocations reaching €200 million by 2027. This supportive environment is expected to enhance collaboration between public and private sectors, further driving market growth.

### Increased Focus on Rare Diseases

The rising focus on rare diseases is a notable driver for the rna based-therapeutics market in Italy. With approximately 7,000 rare diseases identified, many of which lack effective treatments, there is a growing urgency to develop targeted rna-based therapies. The Italian healthcare system is prioritizing research and development in this area, leading to increased funding and collaboration among stakeholders. This focus is likely to result in a market growth rate of around 12% over the next few years, as more rna-based solutions are developed to address the unmet medical needs of patients with rare diseases.

### Advancements in Delivery Mechanisms

Innovations in delivery mechanisms for rna-based therapies are significantly impacting the RNA-based therapeutics market. Enhanced delivery systems, such as lipid nanoparticles and viral vectors, are improving the efficacy and safety of rna therapies. These advancements facilitate targeted delivery to specific tissues, minimizing off-target effects and enhancing therapeutic outcomes. As a result, the market is witnessing increased interest from pharmaceutical companies, with investments in research and development expected to exceed €500 million in the coming years. This focus on improving delivery methods is likely to bolster the adoption of rna-based therapies across various therapeutic areas.

### Rising Prevalence of Genetic Disorders

The prevalence of genetic disorders in Italy is a significant driver for the RNA-based therapeutics market. With an estimated 1 in 200 individuals affected by rare genetic conditions, the demand for innovative therapies is on the rise. The Italian healthcare system is increasingly focusing on developing targeted treatments that address these disorders, which often have limited treatment options. This growing need for effective therapies is likely to stimulate investment in rna-based solutions, potentially leading to a market growth rate of around 15% annually. The rna based-therapeutics market is thus positioned to play a crucial role in addressing these healthcare challenges.

### Growing Demand for Personalized Medicine

The increasing emphasis on [personalized medicine](https://www.marketresearchfuture.com/reports/telemedicine-market-2216)is driving the RNA-based therapeutics market in Italy. Patients are increasingly seeking treatments tailored to their genetic profiles, which enhances the efficacy of therapies. This trend is supported by advancements in genomic research and the ability to analyze individual genetic variations. As a result, the rna based-therapeutics market is expected to witness substantial growth, with projections indicating a market value of approximately €1.5 billion by 2026. The integration of rna-based therapies into personalized treatment plans is likely to enhance patient outcomes and satisfaction, thereby propelling market expansion.

## Future Outlook

The [RNA Based Therapeutics Market](https://www.marketresearchfuture.com/reports/rna-based-therapeutics-market-19244) in Italy is projected to grow at a 6.44% CAGR from 2025 to 2035, driven by advancements in genetic research and increasing healthcare investments.

**New opportunities:**

- Development of personalized rna therapies for rare diseases
- Expansion of RNA delivery systems in clinical settings
- Strategic partnerships with biotech firms for innovative product pipelines

By 2035, the market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Technology: mRNA Therapeutics (Largest) vs. CRISPR Technology (Fastest-Growing)

In the Italy RNA-based therapeutics market, mRNA therapeutics accounts for the largest share of the overall technology segment. This segment has gained significant traction due to advancements in vaccine development and targeted therapies. On the other hand, CRISPR technology, while currently smaller in market share, is rapidly gaining attention due to its potential for gene editing and therapeutic applications, which are anticipated to revolutionize treatment methodologies.

The growth trends in this segment are driven by increased research investments, favorable regulatory environments, and the rising demand for personalized medicine. mRNA therapeutics have experienced accelerated growth owing to their success in combating infectious diseases, while the versatility and efficiency of CRISPR technology suggest it will be the fastest-growing subsector, with numerous applications in genetic disorders, oncology, and beyond. This dynamic landscape highlights the innovative approaches taking place within the Italy rna based-therapeutics market.

Technology: mRNA Therapeutics (Dominant) vs. CRISPR Technology (Emerging)

mRNA therapeutics remain the dominant force within the Italy rna based-therapeutics market, largely due to their role in vaccine development, particularly highlighted during health crises. Their ability to elicit a robust immune response and adaptability for various therapeutic applications make them a preferred choice for many healthcare providers. In contrast, CRISPR Technology, as an emerging segment, showcases exceptional promise with its gene-editing capabilities. Its rapid evolution is fueled by breakthroughs in research, allowing for precise modifications at the genetic level. With applications stretching across diverse medical conditions, CRISPR Technology represents the next frontier for innovative treatments, indicating a significant shift in therapeutic strategies that could challenge existing norms in the industry.

### By Application: Oncology (Largest) vs. Infectious Diseases (Fastest-Growing)

In the Italy RNA-based therapeutics market, the application segments demonstrate a diverse distribution of market share. Oncology currently holds the largest share, driven by a robust pipeline of RNA-based therapies targeting cancer, alongside increasing investments in research and development. Infectious diseases follow closely, capturing significant attention as RNA therapeutics evolve to combat emerging viral threats, thus positioning itself as a critical area of focus for pharmaceutical companies in Italy.

Growth trends in the application segment are notably promising. Oncology is fueled by expanding clinical trials and a heightened focus on personalized medicine, leading to increased adoption of RNA therapeutics. Conversely, the infectious diseases segment is experiencing rapid growth due to the urgent need for innovative therapies in response to outbreaks and pandemics, further accelerated by advancements in RNA technology and rising public health awareness.

Oncology (Dominant) vs. Infectious Diseases (Emerging)

Oncology remains the dominant segment within the Italy rna based-therapeutics market, characterized by its significant investment in developing targeted therapies that utilize RNA technology to tackle various types of cancers. The segment benefits from an established infrastructure and a strong collaboration between research institutions and biotech firms. On the other hand, infectious diseases represent an emerging segment, highlighted by its rapid advancement due to recent global health challenges. This growth is supported by innovative RNA therapeutic approaches aimed at infectious agents, establishing a competitive landscape that encourages rapid development and commercialization of novel treatments, thus showcasing potential for significant contributions to public health.

### By End Use: Pharmaceutical Companies (Largest) vs. Research Institutions (Fastest-Growing)

In the Italy RNA-based therapeutics market, the market share distribution reveals that pharmaceutical companies hold a significant portion of the market, capitalizing on established infrastructures and extensive resources. Meanwhile, research institutions account for a smaller but rapidly rising segment as they increasingly focus on innovative therapies and cutting-edge scientific exploration. Their contribution to the market dynamics is becoming more pronounced, indicating a shift towards a more research-driven landscape.

Growth trends for these segments are influenced by various factors, including the increasing demand for personalized medicine and advancements in genomic research. Pharmaceutical companies are leveraging their capabilities to expand rna-based products, while research institutions are at the forefront of experimentation, leading to faster innovations. As a result, the competition within the market is intensifying, with both segments expected to play pivotal roles in the future of therapeutic developments.

Pharmaceutical Companies: Dominant vs. Research Institutions: Emerging

Pharmaceutical companies in the Italy rna based-therapeutics market are characterized by their robust production capabilities and established market presence. Their dominance stems from significant investments in research and development, allowing them to introduce a range of rna-based therapeutics to treat various diseases. On the other hand, research institutions are emerging as vital players, driving innovation and exploring novel applications of rna technologies. They often collaborate with pharmaceutical companies to translate research findings into viable therapeutic options. The partnership between these two segments enhances the overall market dynamics, as pharmaceutical companies benefit from innovative insights while research institutions gain access to financial resources needed for development.

### By Delivery Method: Liposomes (Largest) vs. Nanoparticles (Fastest-Growing)

In the Italy RNA-based therapeutics market, delivery methods are crucial for the effective administration of therapeutic agents. Currently, liposomes dominate the market, accounting for a significant share thanks to their biocompatibility and ability to encapsulate a variety of drugs. Nanoparticles, while smaller in market share, are making substantial inroads, driven by advancements in nanotechnology that enhance their functional capabilities and targeting precision.

The growth trends for these delivery methods are influenced by increasing research and development activities focused on RNA-based therapies. As clinicians and researchers seek more effective treatment modalities, the flexibility and efficiency of nanoparticles are emerging as key drivers of their rapid adoption. Meanwhile, liposomes may maintain their dominance due to established market presence and extensive clinical applications that continue to reassure investors and stakeholders.

Delivery Method: Liposomes (Dominant) vs. Nanoparticles (Emerging)

Liposomes have long been the dominant delivery method in the Italy rna based-therapeutics market, favored for their excellent encapsulation efficiency and ability to deliver both therapeutic RNA and small molecules effectively. Their stability and biocompatibility render them suitable for various formulations, providing broad applications across different therapeutic areas. On the other hand, nanoparticles are carving out their niche as an emerging method, propelled by innovations that allow for enhanced cellular uptake and targeted delivery. This makes nanoparticles particularly appealing for gene therapy applications, allowing for precise delivery to specific cell types, thereby improving treatment efficacy. As research progresses, both these delivery methods are expected to play vital roles in the evolving landscape of RNA therapeutics.

## Competitive Benchmarking

The rna based-therapeutics market in Italy is characterized by a dynamic competitive landscape, driven by innovation and strategic collaborations among key players. Companies such as Moderna (US), BioNTech (DE), and Alnylam Pharmaceuticals (US) are at the forefront, leveraging their technological advancements to enhance therapeutic offerings. Moderna (US) has focused on expanding its mRNA platform beyond infectious diseases, indicating a strategic pivot towards oncology and rare diseases, which could reshape its market positioning. BioNTech (DE), known for its pioneering work in mRNA technology, has been actively pursuing partnerships to broaden its pipeline, suggesting a commitment to collaborative innovation. Alnylam Pharmaceuticals (US) continues to emphasize its leadership in RNA interference (RNAi) therapeutics, which may solidify its competitive edge in treating genetic disorders.
In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain resilience and reduce operational costs. This trend appears to be a response to global supply chain disruptions, with firms investing in regional production capabilities. The market structure is moderately fragmented, with several players vying for dominance, yet the collective influence of major companies is shaping a more consolidated competitive environment.
In October 2025, Moderna (US) announced a strategic partnership with a leading Italian biotech firm to co-develop mRNA-based therapies for rare genetic disorders. This collaboration is likely to enhance Moderna's presence in the Italian market while leveraging local expertise, which could accelerate the development timeline for new therapies. Similarly, in September 2025, BioNTech (DE) expanded its research facilities in Italy, indicating a commitment to increasing its operational footprint and fostering innovation within the region. This move may enhance its ability to attract top talent and streamline its research processes.
In August 2025, Alnylam Pharmaceuticals (US) launched a new initiative aimed at increasing access to its RNAi therapies in Italy, which could significantly impact patient outcomes. This initiative reflects a broader trend towards patient-centric approaches in the rna based-therapeutics market, emphasizing the importance of accessibility and affordability in therapeutic development. Furthermore, in July 2025, Sangamo Therapeutics (US) entered into a collaboration with an Italian research institution to explore novel gene-editing techniques, which may position the company favorably in the evolving landscape of genetic therapies.
As of November 2025, current trends in the rna based-therapeutics market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, it appears that competitive differentiation will likely evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver personalized therapies. This shift may redefine the parameters of success in the rna based-therapeutics market, emphasizing the need for agility and adaptability in a rapidly changing environment.

## Recent News & Developments

The Italy [RNA-Based Therapeutics](https://www.marketresearchfuture.com/reports/rna-based-therapeutics-market-19244) Market has witnessed significant developments in recent months, showcasing advancements and collaborations among key players. For instance, in October 2023, BioNTech announced a partnership with Italian research institutions to enhance RNA therapy for cancer treatment, signaling a commitment to local innovation. Meanwhile, Moderna continues to expand its footprint in Italy, particularly in the realm of messenger RNA-based vaccines and treatments.

The growth of companies such as Alnylam Pharmaceuticals and Silence Therapeutics in the region has contributed to the market's valuation, with increasing investments and research initiatives. Notably, there have been no major merger or acquisition activities reported in Italy among the focused companies recently. However, Dicerna Pharmaceuticals recently received regulatory approval for its RNA-based therapy targeting rare genetic disorders, further highlighting the dynamic landscape of the market.

The Italian government's support for biotechnology through funding initiatives and regulatory reforms has fostered a favorable environment for these companies to thrive. The combination of local research efforts and multinational partnerships is pivotal for driving growth and innovation within the RNA-Based Therapeutics sector in Italy.

## Report Scope

| MARKET SIZE 2024 | 439.59(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 467.9(USD Million) |
| MARKET SIZE 2035 | 873.25(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.44% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Moderna (US), BioNTech (DE), Alnylam Pharmaceuticals (US), Ionis Pharmaceuticals (US), Sangamo Therapeutics (US), CureVac (DE), Arcturus Therapeutics (US), Translate Bio (US) |
| Segments Covered | Technology, Application, End Use, Delivery Method |
| Key Market Opportunities | Advancements in RNA delivery systems enhance therapeutic efficacy and expand treatment options in the rna based-therapeutics market. |
| Key Market Dynamics | Regulatory advancements and technological innovations drive growth in the RNA-based therapeutics market. |
| Countries Covered | Italy |

## Frequently Asked Questions

**Q: What is the current valuation of the RNA based-therapeutics market in Italy?**
A: The overall market valuation was $439.59 Million in 2024.

**Q: What is the projected market valuation for RNA based-therapeutics in Italy by 2035?**
A: The projected valuation for 2035 is $873.25 Million.

**Q: What is the expected CAGR for the RNA based-therapeutics market in Italy during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 6.44%.

**Q: Which technology segment had the highest valuation in the RNA based-therapeutics market in 2024?**
A: In 2024, the mRNA Therapeutics segment had the highest valuation at $150.0 Million.

**Q: What is the valuation range for the Antisense Oligonucleotides segment in 2024?**
A: The valuation range for the Antisense Oligonucleotides segment in 2024 was $120.0 Million to $250.0 Million.

**Q: Which application segment is projected to grow the most by 2035 in the RNA based-therapeutics market?**
A: The Oncology application segment is projected to grow significantly, with a valuation range of $100.0 Million to $200.0 Million in 2024.

**Q: What are the key players in the RNA based-therapeutics market in Italy?**
A: Key players include Moderna, BioNTech, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals.

**Q: What delivery method segment had the highest valuation in 2024?**
A: The Viral Vectors delivery method segment had the highest valuation at $150.0 Million in 2024.

**Q: What is the valuation range for the Genetic Disorders application segment in 2024?**
A: The valuation range for the Genetic Disorders application segment in 2024 was $90.0 Million to $180.0 Million.

**Q: Which end-use segment had the highest valuation in the RNA based-therapeutics market in 2024?**
A: The Pharmaceutical Companies end-use segment had the highest valuation at $263.63 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/italy-rna-based-therapeutics-market-52653*